High Tide's German Subsidiary Hits Record Medical Cannabis Distribution
Event summary
- High Tide's 51%-owned subsidiary Remexian Pharma GmbH distributed 7.6 tonnes of medical cannabis in Q2 2026, a 21% sequential and 49% year-over-year increase.
- Germany imported 201.1 tonnes of medical cannabis in 2025, nearly doubling the previous year's 72.9 tonnes, with over 93 tonnes sourced from Canada.
- Remexian holds over 10% market share in German medical cannabis imports and is licensed to import from 19 countries, including Canada.
- High Tide plans to expand its distribution model across Europe, subject to regulatory conditions.
The big picture
High Tide's record distribution figures underscore its strategic positioning in Europe's largest medical cannabis market. The company's ability to leverage its Canadian procurement capabilities and scale its distribution model will be critical as it seeks to capture market share in Germany and beyond. The rapid growth in German medical cannabis imports highlights the region's potential as a key growth driver for international cannabis operators.
What we're watching
- Market Expansion
- Whether High Tide can sustain its growth momentum in Germany while entering additional high-growth European markets.
- Regulatory Compliance
- The pace at which regulatory conditions will allow High Tide to expand its distribution model across Europe.
- Operational Efficiency
- How High Tide's capital-efficient distribution engine will perform under increased market demand and competitive pressures.
Related topics